IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  McCoy, Erin M ^a   Hong, Huixian ^a,b   Pruitt, Hawley C ^a   Feng, Xu ^a  

^a University of Alabama at Birmingham   (United States)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Bone metastasis; Bone resorption; Breast cancer; Interleukin 11; Osteoclast; Osteolysis; RANKL

Indexed keywords

COLONY STIMULATING FACTOR 1; INTERLEUKIN 11; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE TISSUE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; MACROPHAGE; METASTASIS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST PROGENITOR CELL; OSTEOCLASTOGENESIS; STEM CELL; TISSUE CULTURE; TISSUE SLICE;

ANIMALS; ANTIBODIES, NEUTRALIZING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; INTERLEUKIN-11; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OSTEOLYSIS; PARACRINE COMMUNICATION; RANK LIGAND; RECOMBINANT PROTEINS; STEM CELLS; TIME FACTORS;

EID: 84872141368     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-16     Document Type: Article

References (37)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2(8):584-593. 10.1038/nrc867, 12154351.
2. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11(6):411-425. 10.1038/nrc3055, 21593787.
3. Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Kollermann MW, et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A 2002, 99(4):2246-2251. 10.1073/pnas.042372199, 122350, 11854519.
4. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004, 350(16):1655-1664. 10.1056/NEJMra030831, 15084698.
5. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549. 10.1016/S1535-6108(03)00132-6, 12842083.
6. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 2001, 100(1):18-24. 10.1006/jsre.2001.6204, 11516200.
7. Pederson L, Winding B, Foged NT, Spelsberg TC, Oursler MJ. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res 1999, 59(22):5849-5855.
8. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988, 241(4867):825-828. 10.1126/science.3136546, 3136546.
9. Hilton DJ, Hilton AA, Raicevic A, Rakar S, Harrison-Smith M, Gough NM, Begley CG, Metcalf D, Nicola NA, Willson TA. Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J 1994, 13(20):4765-4775. 395415, 7957045.
10. Leng SX, Elias JA. Interleukin-11. Int J Biochem Cell Biol 1997, 29(8-9):1059-1062.
11. Morinaga Y, Fujita N, Ohishi K, Tsuruo T. Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-beta and tumor cell factors. Int J of cancer J Int du cancer 1997, 71(3):422-428.
12. Hughes FJ, Howells GL. Interleukin-11 inhibits bone formation in vitro. Calcif Tissue Int 1993, 53(5):362-364. 10.1007/BF01351844, 8287326.
13. Lacroix M, Siwek B, Marie PJ, Body JJ. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett 1998, 127(1-2):29-35.
14. Sims NA, Jenkins BJ, Nakamura A, Quinn JM, Li R, Gillespie MT, Ernst M, Robb L, Martin TJ. Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res 2005, 20(7):1093-1102. 10.1359/JBMR.050209, 15940362.
15. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003, 32(1):1-7. 10.1016/S8756-3282(02)00915-8, 12584029.
16. Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest 1994, 93(4):1516-1524. 10.1172/JCI117130, 294166, 8163655.
17. Morgan H, Tumber A, Hill PA. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor. Int J of cancer J Int du cancer 2004, 109(5):653-660.
18. Hill PA, Tumber A, Papaioannou S, Meikle MC. The cellular actions of interleukin-11 on bone resorption in vitro. Endocrinology 1998, 139(4):1564-1572. 10.1210/en.139.4.1564, 9528935.
19. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000, 105(4):433-440. 10.1172/JCI8905, 289172, 10683372.
20. Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. J Cell Physiol 1998, 175(3):247-254. 10.1002/(SICI)1097-4652(199806)175:3<247::AID-JCP2>3.0.CO;2-O, 9572469.
21. Ma T, Miyanishi K, Suen A, Epstein NJ, Tomita T, Smith RL, Goodman SB. Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-alpha. Cytokine 2004, 26(3):138-144. 10.1016/j.cyto.2004.02.001, 15135808.
22. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005, 115(2):282-290. 544608, 15668736.
23. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106(12):1481-1488. 10.1172/JCI11176, 387259, 11120755.
24. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 2004, 19(2):207-213.
25. Jules J, Shi Z, Liu J, Xu D, Wang S, Feng X. Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis. J Biol Chem 2010, 285(48):37427-37435. 10.1074/jbc.M110.149484, 2988348, 20870724.
26. Jules J, Zhang P, Ashley JW, Wei S, Shi Z, Liu J, Michalek SM, Feng X. Molecular basis of requirement of receptor activator of nuclear factor kappaB signaling for interleukin 1-mediated osteoclastogenesis. J Biol Chem 2012, 287(19):15728-15738. 10.1074/jbc.M111.296228, 22416138.
27. Crichton MB, Nichols JE, Zhao Y, Bulun SE, Simpson ER. Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells. Mol Cell Endocrinol 1996, 118(1-2):215-220.
28. Sotiriou C, Lacroix M, Lagneaux L, Berchem G, Body JJ. The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and -11. Anticancer Res 1999, 19(4B):2997-3006.
29. Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ. Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett 2001, 169(1):87-95. 10.1016/S0304-3835(01)00524-9, 11410329.
30. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005, 102(39):13909-13914. 10.1073/pnas.0506517102, 1236573, 16172383.
31. Singh B, Berry JA, Shoher A, Lucci A. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res 2006, 131(2):267-275. 10.1016/j.jss.2005.11.582, 16457848.
32. Hanavadi S, Martin TA, Watkins G, Mansel RE, Jiang WG. Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann Surg Oncol 2006, 13(6):802-808. 10.1245/ASO.2006.05.028, 16614887.
33. Gupta J, Robbins J, Jilling T, Seth P. TGFbeta-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential. Cancer Biol Ther 2011, 11(3):311-316. 10.4161/cbt.11.3.14096, 3047085, 21099351.
34. Pollari S, Kakonen RS, Mohammad KS, Rissanen JP, Halleen JM, Warri A, Nissinen L, Pihlavisto M, Marjamaki A, Perala M, et al. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res 2012, 10(5):597-604. 10.1158/1541-7786.MCR-11-0482, 22522458.
35. Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ, Suda T, Ng KW, Martin TJ. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med 1996, 183(6):2581-2591. 10.1084/jem.183.6.2581, 2192607, 8676079.
36. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20(3):345-357. 10.1210/er.20.3.345, 10368775.
37. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999, 25(1):109-113. 10.1016/S8756-3282(99)00121-0, 10423033.